Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Vosevi“
Suchtreffer
Begriffe & Kennungen
Vosevi · 4.5 · Patients treated with vitamin K antagonists
Eintrag öffnenVosevi · 4.5 · Pharmacokinetic interactions
Eintrag öffnenVosevi · 4.5 · Potential for Vosevi to affect other medicinal products
Eintrag öffnenVosevi · 4.5 · Potential for other medicinal products to affect Vosevi
Eintrag öffnenVosevi · 4.5 · Proton pump inhibitors Omeprazole Observed: Proton pump inhibitors may be (20 mg once daily) + Sofosbuvir ↓ ↓
Eintrag öffnenVosevi · 4.5 · Sofosbuvir, velpatasvir and voxilaprevir are substrates of drug transporters P-gp and BCRP. Velpatasvir and vo
Eintrag öffnenVosevi · 4.5 · Table 2 provides a listing of established or potentially clinically significant medicinal product interactions
Eintrag öffnenVosevi · 4.5 · Table 2: Interactions between Vosevi and other medicinal products
Eintrag öffnenVosevi · 4.5 · The pharmacokinetics of medicinal products that are metabolized by the liver (e.g. immunosuppressive agents su
Eintrag öffnenVosevi · 4.5 · Velpatasvir and voxilaprevir are inhibitors of drug transporters P-gp, breast cancer resistance protein (BCRP)
Eintrag öffnenVosevi · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenVosevi · 4.8 Undesirable effects · 1
Eintrag öffnenVosevi · 4.8 · 18 exposure of sofosbuvir metabolite GS-331007 is 20-fold increased, exceeding levels where adverse reactions
Eintrag öffnenVosevi · 4.8 · Assessment of adverse reactions for Vosevi is based on safety data from clinical studies and post- marketing e
Eintrag öffnenVosevi · 4.8 · Cardiac arrhythmias Cases of severe bradycardia and heart block have been observed when sofosbuvir containing
Eintrag öffnenVosevi · 4.8 · Description of selected adverse reactions
Eintrag öffnenVosevi · 4.8 · Frequency Adverse reaction Nervous system disorders: Very common headache Gastrointestinal disorders: Very com
Eintrag öffnenVosevi · 4.8 · In Phase 2 and 3 clinical studies, the proportion of patients who permanently discontinued treatment due to ad
Eintrag öffnenVosevi · 4.8 · Laboratory abnormalities
Eintrag öffnenVosevi · 4.8 · Paediatric population
Eintrag öffnen